This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

This study has been completed.
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research Identifier:
First received: November 1, 1999
Last updated: May 14, 2012
Last verified: May 2012

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine and vinorelbine and to see how well they work in treating older women with metastatic breast cancer with or without bone involvement.

Condition Intervention Phase
Breast Cancer Drug: capecitabine Drug: vinorelbine tartrate Phase 1 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase I/II of Capecitabine and Vinorelbine in Elderly Patients (At Least 65 Years) With Metastatic Breast Cancer With or Without Bone Involvement

Resource links provided by NLM:

Further study details as provided by Swiss Group for Clinical Cancer Research:

Primary Outcome Measures:
  • Maximum-tolerated dose (phase I)
  • Response rate at the end of study treatment (phase II)
  • Toxicity at the end of study treatment (phase II)

Secondary Outcome Measures:
  • Time to treatment failure at end of study treatment (phase II)
  • Quality of life by Linear Analogue Self-Assessment indicators with 6 assessments until the end of the course 4 (phase II)

Estimated Enrollment: 110
Study Start Date: March 1999
Study Completion Date: September 2005
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the maximum tolerated dose of capecitabine and vinorelbine in elderly women (65 and older) with metastatic breast cancer.
  • Evaluate the efficacy and tolerability of this regimen in these patients.
  • Assess the time to treatment failure for this regimen as a first line chemotherapy in these patients.

OUTLINE: This is a dose-escalation study of capecitabine and vinorelbine. Patients are stratified according to bone involvement (yes [closed to accrual as of 12/7/04] vs no).

  • Phase I: Patients receive oral capecitabine twice daily on days 1-14 and vinorelbine IV over 6-10 minutes on days 1 and 8. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of capecitabine and vinorelbine until the maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity.

  • Phase II: Patients receive capecitabine and vinorelbine administered as in phase I, at the dose preceding the MTD.

Quality of life is assessed during phase II on days 1, 8, and 15 of course 1 and on day 1 of courses 2-4.

Patients are followed every 3 months until disease progression or start of any subsequent antitumor treatment.

PROJECTED ACCRUAL: A total of 98-110 patients will be accrued for this study.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically or cytologically proven adenocarcinoma of the breast
  • Phase I: Measurable or evaluable disease
  • Phase II: Bidimensionally measurable disease
  • No CNS metastases
  • Hormone receptor status:

    • Not specified



  • 65 and over


  • Female

Menopausal status:

  • Postmenopausal

Performance status:

  • ECOG/SAKK 0-2

Life expectancy:

  • At least 12 weeks


  • Normal peripheral blood counts


  • AST no greater than 2 times upper limit of normal (ULN) (no greater than 3 times ULN if liver metastases present)


  • Creatinine no greater than 1.5 times ULN


  • No other prior or concurrent malignancy except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix
  • No peripheral neuropathy grade 2 or higher
  • No cognitive impairment or severe psychiatric disorder


Biologic therapy:

  • Not specified


  • More than 6 months since prior adjuvant chemotherapy
  • No prior chemotherapy for metastatic or locally advanced disease
  • No other concurrent chemotherapy

Endocrine therapy:

  • Prior hormonal therapy for metastatic disease allowed
  • No continuous concurrent steroids
  • No concurrent systemic endocrine therapy for breast cancer
  • No other concurrent endocrine therapy


  • No concurrent radiotherapy involving greater than 30% of bone marrow or mucosa
  • Radiotherapy to nonindicator lesion allowed


  • Not specified


  • Bisphosphonates allowed if indicator lesion in nonbone site
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00003902

Kantonsspital - St. Gallen
St. Gallen, Switzerland, CH-9007
Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
Study Chair: Dagmar Hess, MD Cantonal Hospital of St. Gallen
  More Information

Responsible Party: Swiss Group for Clinical Cancer Research Identifier: NCT00003902     History of Changes
Other Study ID Numbers: SAKK 25/99
Study First Received: November 1, 1999
Last Updated: May 14, 2012

Keywords provided by Swiss Group for Clinical Cancer Research:
stage IV breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators processed this record on September 21, 2017